AusCann advances the development of cannabinoid hard shell capsules
Highlights
• Agreement with PCI Pharma to manufacture AusCann’s cannabinoid hard shell capsules
• DayaCann and Khiron Life Sciences to commence first cultivation activities under the MoU signed at the start of the Quarter
• Expanded medical educational program to drive engagement with medical practitioners in Australia
• CEO transition to support AusCann’s next phase of growth as a pharmaceutical company continued to progress and is now at an advanced stage
• AusCann on track for the production of cannabinoid medicines for use in clinical trials during this calendar year
31 January 2019 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (‘AusCann’ or ‘the Company’) is pleased to provide an overview of its activities for the three months ended 31 December 2018.
For further information please download PDF attached:
Download this document
